Analysis of albumin-associated peptides and proteins from ovarian cancer patients
about
Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresisIn 2014, can we do better than CA125 in the early detection of ovarian cancer?What is hidden in the pannexin treasure trove: the sneak peek and the guessworkReverse phase protein microarrays advance to use in clinical trialsOptimization of plasma sample pretreatment for quantitative analysis using iTRAQ labeling and LC-MALDI-TOF/TOFTop-down proteomics with mass spectrometry imaging: a pilot study towards discovery of biomarkers for neurodevelopmental disordersProteomic analysis of polypeptides captured from blood during extracorporeal albumin dialysis in patients with cholestasis and resistant pruritusDiverse range of small peptides associated with high-density lipoprotein.Human body fluid proteome analysis.Serum albumin-associated peptides of patients with uterine endometrial cancer.Reduced transthyretin expression in sera of lung cancer.Experimental-confirmation and functional-annotation of predicted proteins in the chicken genome.Enrichment and detection of molecules secreted by tumor cells using magnetic reversed-phase particles and LC-MALDI-TOF-MS.Proteomics Discovery of Disease Biomarkers.High-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery.Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology.Prostate cancer serum biomarker discovery through proteomic analysis of alpha-2 macroglobulin protein complexes.Investigation of an albumin-enriched fraction of human serum and its albuminome.Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discoverySmart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradationQuantitative peptidomic analysis by a newly developed one-step direct transfer technology without depletion of major blood proteins: its potential utility for monitoring of pathophysiological status in pregnancy-induced hypertension.Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancerMS/MS library facilitated MRM quantification of native peptides prepared by denaturing ultrafiltration.Soluble plasma HLA peptidome as a potential source for cancer biomarkersClinical peptidomic analysis by a one-step direct transfer technology: its potential utility for monitoring of pathophysiological status in female reproductive system disorders.A fast and reproducible method for albumin isolation and depletion from serum and cerebrospinal fluid.Simple quantitation for potential serum disease biomarker peptides, primarily identified by a peptidomics approach in the serum with hypertensive disorders of pregnancy.IgY14 and SuperMix immunoaffinity separations coupled with liquid chromatography-mass spectrometry for human plasma proteomics biomarker discovery.A method for isolation and identification of urinary biomarkers in patients with diabetic nephropathy.Current state of the art for enhancing urine biomarker discovery.MALDI-MS-Based Profiling of Serum Proteome: Detection of Changes Related to Progression of Cancer and Response to Anticancer Treatment.Peptide profiling of cerebrospinal fluid by mass spectrometry.Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer.Frozen tissue biobanks. Tissue handling, cryopreservation, extraction, and use for proteomic analysis.A vision for better health: mass spectrometry imaging for clinical diagnostics.The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's diseaseConventional and proteomic technologies for the detection of early stage malignancies: markers for ovarian cancer.Tumor-associated antigens and biomarkers in cancer and immune therapy.Assessment of albumin removal from an immunoaffinity spin column: critical implications for proteomic examination of the albuminome and albumin-depleted samples.Tumour and dendrimers: a review on drug delivery aspects.
P2860
Q24600418-8F6F3853-0931-4E54-B746-D57778CDD02AQ26825152-3029E166-4EB0-4452-A096-31BDBE557747Q28264681-76E72DAD-D79B-4ED0-9DEC-37DEAFBA056AQ28384553-447FB375-BDD3-4580-80B7-8BA4E7328A01Q28540277-FC6AC8B1-3FF3-4D5D-A3FB-2989E95227ADQ28542079-043AD890-4ADA-4D26-90F5-07D697F3E1FEQ28742619-972A82A1-47B9-4AAA-9B3A-8B150D0ED994Q33230587-E458C187-FE44-410B-B9E6-0E0D2B3EF71CQ33262623-E0BD8506-1879-4D2F-9F2A-BFF5C8C817D2Q33281557-4CA77DD6-0444-4CB0-9B0B-24AD0BE5DF5AQ33293388-F2628526-50C2-416D-8FE2-417044D59830Q33306165-EE6955E8-1D47-4B1B-A40C-FEE2462A30ECQ33312897-BC972E25-50D5-4659-872C-B36729942C5EQ33478412-6FC95DEC-97F5-4791-8F05-17D92814268FQ33579375-167ADD48-07FB-42B2-8FEF-F8A1F341D1A1Q33605010-C3F9B3C4-E09D-4471-B902-33D3C867EF7BQ33611314-62F426AA-E42E-49CB-9CCD-50693E25E929Q33701508-A71A198B-2DA0-4246-ABCA-628FEFE779B8Q33862871-71B0B485-8568-4760-A1BC-B302A02E9F63Q33882805-BCA4D582-79AF-4FE5-A885-59B1ECC407BDQ33918651-2FBAF719-80FC-4AC5-A508-4AFAC3FB84A4Q34005862-9715A05B-8832-4C93-839B-6748C0C98537Q34150493-94F687DA-117B-4A95-AEBE-3252E51A5EABQ34279102-61C98C3F-FB54-4447-9F60-4E7F974BF559Q34986725-BC13F7ED-8656-4DB5-B74F-1C8FCF529CC6Q35156254-1460BA77-0182-4DD3-99C0-AFB5E4153FDCQ35594685-4F8BB34A-EC9E-405D-A38A-8CB7008BF10EQ35680919-44ED7B03-19E4-466E-BB79-1394927B5E49Q35896647-00AD0EA8-CCF8-4D62-B9F1-582108E82DD1Q36032361-A519255D-FC65-4872-93ED-3D7C4F1CD670Q36147848-49E895E2-F20B-49A3-8D89-3473ADA6D8CDQ36505671-39088ABE-57A2-4450-B078-0571430FFE65Q36528900-20C427E5-D20D-4B44-99C6-AC61446DCE07Q36580350-1D80283A-F164-442E-87A5-451712FC3B96Q36617136-7666B0ED-DF6A-407F-A77D-1A802C9F9FC4Q36660120-381671FB-B122-4CB4-A0F7-581F0566A94DQ36686826-71FA06EC-E8F3-412E-B6E8-0F2A3D066076Q36844959-59460166-EF93-407E-87AD-623F2EA9E825Q36931787-80025809-BFD9-4E32-B816-BF5343C73E01Q37171165-DA3716EA-1A9D-4914-908C-006D1D7265C0
P2860
Analysis of albumin-associated peptides and proteins from ovarian cancer patients
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Analysis of albumin-associated peptides and proteins from ovarian cancer patients
@ast
Analysis of albumin-associated peptides and proteins from ovarian cancer patients
@en
Analysis of albumin-associated peptides and proteins from ovarian cancer patients
@en-gb
Analysis of albumin-associated peptides and proteins from ovarian cancer patients
@nl
type
label
Analysis of albumin-associated peptides and proteins from ovarian cancer patients
@ast
Analysis of albumin-associated peptides and proteins from ovarian cancer patients
@en
Analysis of albumin-associated peptides and proteins from ovarian cancer patients
@en-gb
Analysis of albumin-associated peptides and proteins from ovarian cancer patients
@nl
prefLabel
Analysis of albumin-associated peptides and proteins from ovarian cancer patients
@ast
Analysis of albumin-associated peptides and proteins from ovarian cancer patients
@en
Analysis of albumin-associated peptides and proteins from ovarian cancer patients
@en-gb
Analysis of albumin-associated peptides and proteins from ovarian cancer patients
@nl
P2093
P1433
P1476
Analysis of albumin-associated peptides and proteins from ovarian cancer patients
@en
P2093
Arpita I Mehta
Brian L Hood
David Fishman
Emanuel F Petricoin
Kristina Frogale
Lance A Liotta
Mark S Lowenthal
Paul Goldsmith
Robyn P Araujo
Russell W Bandle
P304
P356
10.1373/CLINCHEM.2005.052944
P407
P577
2005-10-01T00:00:00Z